GlycoMimetics is evaluating its drug candidate
in adults with acute myeloid leukemia.
Our pivotal trial for uproleselan is being conducted under the auspices of the FDA’s Breakthrough Therapy designation.
(formerly GMI-1070) is the only on-demand therapy in late-stage clinical development to treat VOC, a severe complication of sickle cell disease.
We are applying our expertise in carbohydrate biology and chemistry to design high-potency
inhibitors of galectin-3.
These therapies could be instrumental in treating fibrosis and various forms of cancer
Our expertise in glycobiology is behind our development of potentially groundbreaking therapies to treat serious oncology, immunology, and inflammatory, conditions.